Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials.

By M. Castro, J. Zangrilli, M. Wechsler, E. Bateman, G. Brusselle, P. Bardin, K. Murphy, J. Maspero, C. O'Brien, Stephanie Korn. The Lancet Respiratory Medicine, 2015

1,056 citations recorded by the source corpus.

Subfields: Physiology, Rheumatology, Sociology and Political Science

View Paper: https://www.semanticscholar.org/paper/e22217be8c884d8f294398139ba0062dd77a179c